A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)
Titel:
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)
Auteur:
Groen, H.J.M. Socinski, M.A. Grossi, F. Juhasz, E. Gridelli, C. Baas, P. Butts, C.A. Chmielowska, E. Usari, T. Selaru, P. Harmon, C. Williams, J.A. Gao, F. Tye, L. Chao, R.C. Blumenschein Jr, G.R.